Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-879-8 | CAS number: 100-69-6
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- no data
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study under GLP condition. No statistical analysis was conducted on the data.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- Remarks:
- . Statistical analysis was not conducted.
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- 2-vinylpyridine
- EC Number:
- 202-879-8
- EC Name:
- 2-vinylpyridine
- Cas Number:
- 100-69-6
- Molecular formula:
- C7H7N
- IUPAC Name:
- 2-ethenylpyridine
- Details on test material:
- - Physical state: liquid
- Purity: 98.3 %
- Impurities (identity and concentrations): 2-picoline (0.9 %), 2-ethylpyridine (0.4 %), 2-methylpyridine (0.4 %)
- Composition of test material, percentage of components: no data
- Isomers composition: no data
-Manufacture, supplier, source of supply : Yuki Gosei Kogyo Co., Ltd.
- Lot/batch No.: 95-022
Constituent 1
Method
Species / strainopen allclose all
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver, induced with phenobarbital and 5,6-benzoflavone
- Test concentrations with justification for top dose:
- -S9 mix; 39.1, 78.1, 156, 313, 625, 1250 and 2500 μg/plate (TA100 and TA1535)
156, 313, 625, 1250, 2500 and 5000 μg/plate (TA98,TA1537 and WP2 uvrA)
+S9 mix; 156, 313, 625, 1250, 2500 and 5000 μg/plate
+S9 mix (WP2 uvrA; confirmative examination); 2500, 3000, 3500, 4000, 4500 and 5000 μg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: no data
Controlsopen allclose all
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide: -S9 mix: TA100, TA98 and WP2 uvrA
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- Migrated to IUCLID6: -S9 mix : TA1535
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Migrated to IUCLID6: -S9 mix : TA1537
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-Aminoanthracene : +S9 mix : all strains
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation
DURATION
-Preincubation period: 20 minutes
-Exposure duration: 48 hours
NUMBER OF PLATES : 3
DETERMINATION OF CYTOTOXICITY
- Method: growth inhibition - Evaluation criteria:
- The chemicals were considered to be mutagenic when a dose-related increase in revertant colony count was observed and the number of revertant colonies per plate with the test substance was more than twice that of the negative control and when a reproducibility of test result was observed. A test substance for which the results do not meet the above criteria is considered non-mutagenic in this test.
- Statistics:
- Statistical analysis was not conducted.
Results and discussion
Test resultsopen allclose all
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 5000 μg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- -S9: 2500 μg/plate (TA100, TA1535), 5000 μg/plate (TA98, TA1537) +S9: 2500, 5000 μg/plate (TA100, TA1535, 1537), 5000 μg/plate (TA98)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 5000 μg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Remarks on result:
- other: strain/cell type: E. coli WP2 uvr A
- Remarks:
- Migrated from field 'Test system'.
Any other information on results incl. tables
Mutagenic potency calculated by following equation was 10.7. Mutagenic potency = [(number of induced revertants on the dose X) - (number of revertant on the negative control)] / (mg of test chemicals on the dose X)
Table1. Results of the bacterial reversion test of 2-vinylpyridine (1st trial) [direct method: -S9]
| Test substance dose (μg/plate) | Revertant colonies per plate [Mean ± S.D.] | ||||
| TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |
| 0 | 105, 117, 108 [110 ± 6] |
15, 11, 16 [14 ± 3] |
31, 26, 21 [26 ± 5] |
11, 13, 18 [14 ± 4] |
7, 4, 7 [6 ± 2] |
| 39.1 | 126, 109, 118 [118 ± 9] |
16, 17, 15 [16 ± 1] |
- | - | - |
| 78.1 | 122, 118, 129 [123 ± 6] |
15, 20, 12 [16 ± 4] |
- | - | - |
| 156 | 133, 111, 107 [117 ± 14] |
12, 16, 18 [15 ± 3] |
29, 28, 31 [29 ± 2] |
18, 17, 14 [16 ± 2] |
4, 7, 9 [7 ± 3] |
| 313 | 107, 134, 110 [117 ± 15] |
5, 12, 11 [9 ± 4] |
25, 37, 30 [31 ± 6] |
20, 15, 7 [17 ± 3] |
1, 3, 4 [3 ± 2] |
| 625 | 132, 136, 108 [125 ± 15] |
8, 8, 14 [10 ± 3] |
30, 26, 26 [27 ± 2] |
18, 21, 20 [20 ± 2] |
6, 5, 6 [6 ± 1] |
| 1250 | 117, 121, 109 [116 ± 6] |
8, 13, 10 [10 ± 3] |
34, 37, 34 [35 ± 2] |
21, 17, 20 [19 ± 2] |
7, 7, 9 [8 ± 1] |
| 2500 | 44*, 74*, 76* [65 ± 18] |
4*, 9*, 6* [6 ± 3] |
48, 49, 48 [48 ± 1] |
6, 5, 9 [7 ± 2] |
7, 9, 9 [8 ± 1] |
| 5000 | - | - | 33*, 39*, 36* [36 ± 3] |
1*, 3*, 0* [1 ± 2] |
8*, 8*, 8* [8 ± 0] |
| Positive control | 416, 421, 428a) [422 ± 6] |
399, 352, 388b) [380 ± 25] |
132, 128, 124a) [128 ± 4] |
633, 604, 658c) [632 ± 27] |
645, 586, 574d) [602 ± 38] |
*: Toxic effect was observed
-: Not tested
a): AF-2; 2-(2-Furyl)-3-(5-nitro-2 -furyl)acrylamide, 0.01 μg/plate
b): NaN3; Sodium azide, 0.5 μg/plate
c): AF-2, 0.1 μg/plate
d): ACR; 9-Aminoacridine hydrochloride, 80 μg/plate
Table2. Results of the bacterial reversion test of 2-vinylpyridine (1st trial) [activation method: +S9]
| Test substance dose (μg/plate) | Revertant colonies per plate [Mean ± S.D.] | ||||
| TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |
| 0 | 103, 111, 115 [110 ± 6] |
15, 8, 17 [13 ± 5] |
20, 26, 25 [24 ± 3] |
30, 28, 26 [28 ± 2] |
6, 10, 11 [9 ± 3] |
| 156 | 120, 141, 116 [126 ± 13] |
12, 13, 17 [14 ± 3] |
31, 31, 22 [28 ± 5] |
30, 17, 29 [25 ± 7] |
13, 13, 11 [12 ± 1] |
| 313 | 131, 130, 148 [136 ± 10] |
18, 12, 15 [15 ± 3] |
28, 33, 31 [31 ± 3] |
28, 21, 22 [24 ± 4] |
7, 5, 9 [7 ± 2] |
| 625 | 113, 118, 113 [115 ± 3] |
14, 16, 18 [16 ± 2] |
41, 41, 41 [41 ± 0] |
23, 31, 30 [28 ± 4] |
9, 6, 5 [7 ± 2] |
| 1250 | 107, 104, 105 [105 ± 2] |
20, 20, 16 [19 ± 2] |
45, 40, 55 [47 ± 8] |
15, 22, 22 [20 ± 4] |
7, 6, 6 [6 ± 1] |
| 2500 | 85*, 93*, 105* [94 ± 10] |
17*, 20*, 22* [20 ± 3] |
55, 43, 43 [47 ± 7] |
29, 19, 19 [22 ± 6] |
5*, 8*, 5* [6 ± 2] |
| 5000 | 88*, 67*, 57* [71 ± 16] |
6*, 12*, 15* [11 ± 5] |
58*, 62*, 65* [62 ± 4] |
28*, 31*, 24* [28 ± 4] |
9*, 8*, 15* [11 ± 4] |
| Positive control | 763, 842, 816a) [807 ± 40] |
318, 304, 299b) [307 ± 10] |
956, 926, 909c) [930 ± 24] |
391, 394, 433d) [406 ± 23] |
131, 121, 133b) [128 ± 6] |
*: Toxic effect was observed
a): 2-AA; 2-Aminoanthracene, 1 μg/plate
b): 2-AA, 2 μg/plate
c): 2-AA, 10 μg/plate
d): 2-AA, 0.5 μg/plate
Table3. Results of the bacterial reversion test of 2-vinylpyridine (2nd trial) [direct method: -S9]
| Test substance dose (μg/plate) | Revertant colonies per plate [Mean±S.D.] | ||||
| TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |
| 0 | 118, 105, 113 [112 ± 7] |
17, 17, 14 [16 ± 2] |
29, 22, 23 [25 ± 4] |
17, 22, 22 [20 ± 3] |
8, 7, 10 [8 ± 2] |
| 39.1 | 93, 101, 93 [96 ± 5] |
14, 16, 18 [16 ± 2] |
- | - | - |
| 78.1 | 108, 94, 114 [105 ± 10] |
13, 19, 12 [15 ± 4] |
- | - | - |
| 156 | 97, 92, 104 [98 ± 6] |
17, 19, 12 [16 ± 4] |
22, 21, 23 [22 ± 1] |
17, 19, 13 [16 ± 3] |
4, 6, 7 [6 ± 2] |
| 313 | 88, 103, 110 [100 ± 11] |
18, 13, 14 [15 ± 3] |
31, 22, 34 [29 ± 6] |
16, 18, 18 [17 ± 1] |
9, 10, 8 [9 ± 1] |
| 625 | 97, 86, 106 [96 ± 10] |
20, 15, 17 [17 ± 3] |
29, 25, 26 [27 ± 2] |
10, 14, 14 [13 ± 2] |
7, 11, 5 [8 ± 3] |
| 1250 | 106, 96, 97 [100 ± 6] |
17, 10, 12 [13 ± 4] |
24, 36, 29 [30 ± 6] |
8, 12, 8 [9 ± 2] |
9, 5, 5 [6 ± 2] |
| 2500 | 77*, 74*, 73* [75 ± 2] |
8*, 9*, 11* [9 ± 2] |
37, 36, 36 [36 ± 1] |
12, 10, 17 [13 ± 4] |
8, 7, 7 [7 ± 1] |
| 5000 | - | - | 27*, 27*, 29* [28 ± 1] |
5*, 8*, 7* [7 ± 2] |
6*, 9*, 6* [7 ± 2] |
| Positive control | 479, 467, 469a) [472 ± 6] |
428, 402, 409b) [413 ± 13] |
152, 155, 138a) [148 ± 9] |
679, 626, 666c) [657 ± 28] |
662, 591, 630d) [628 ± 36] |
*: Toxic effect was observed
-: Not tested
a): AF-2; 2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide, 0.01 μg/plate
b): NaN3; Sodium azide, 0.5 μg/plate
c): AF-2, 0.1 μg/plate
d): ACR; 9-Aminoacridine hydrochloride, 80 μg/plate
Table4. Results of the bacterial reversion test of 2-vinylpyridine (2nd trial) [activation method: +S9]
| Test substance dose (μg/plate) | Revertant colonies per plate [Mean ± S.D.] | ||||
| TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |
| 0 | 114, 113, 113 [113 ± 1] |
13, 19, 17 [16 ± 3] |
21, 27, 28 [25 ± 4] |
29, 26, 25 [27 ± 2] |
9, 11, 11 [10 ± 1] |
| 156 | 114, 113, 109 [112 ± 3] |
19, 14, 12 [15 ± 4] |
25, 24, 27 [25 ± 2] |
24, 13, 20 [19 ± 6] |
9, 7, 10 [9 ± 2] |
| 313 | 109, 97, 120 [109 ± 12] |
18, 13, 14 [15 ± 3] |
25, 25, 29 [26 ± 2] |
21, 31, 27 [26 ± 5] |
9, 11, 10 [10 ± 1] |
| 625 | 103, 113, 113 [110 ± 6] |
17, 19, 20 [19 ± 2] |
30, 26, 30 [29 ± 2] |
30, 20, 23 [24 ± 5] |
9, 6, 9 [8 ± 2] |
| 1250 | 104, 100, 94 [99 ± 5] |
13, 17, 9 [13 ± 4] |
48, 50, 40 [46 ± 5] |
22, 18, 23 [21 ± 3] |
6, 4, 4 [5 ± 1] |
| 2500 | 116*, 104*, 96* [105 ± 10] |
10*, 9*, 16* [12 ± 4] |
39, 42, 45 [42 ± 3] |
21, 19, 20 [20 ± 1] |
7*, 7*, 3* [6 ± 2] |
| 5000 | 82*, 78*, 72* [77 ± 5] |
10*, 12*, 15* [12 ± 3] |
40*, 47*, 55* [47 ± 8] |
17*, 18*, 19* [18 ± 1] |
7*, 4*, 4* [5 ± 2] |
| Positive control | 812, 799, 765a) [792 ± 24] |
301, 352, 339b) [331 ± 27] |
932, 929, 907c) [923 ± 14] |
398, 413, 398d) [403 ± 9] |
119, 129, 127b) [125 ± 5] |
*: Toxic effect was observed
a): 2-AA; 2-Aminoanthracene, 1 μg/plate
b): 2-AA, 2 μg/plate
c): 2-AA, 10 μg/plate
d): 2-AA, 0.5 μg/plate
Table5. Results of the confirmative examination of 2-vinylpyridine [activation method: +S9]
| Test substance dose (μg/plate) | Revertant colonies per plate [Mean ± S.D.] | ||||
| TA100 | TA1535 | WP2uvrA | TA98 | TA1537 | |
| 0 | - | - | 24, 19, 19 [21 ± 3] |
- | - |
| 2500 | - | - | 45, 49, 39 [44 ± 5] |
- | - |
| 3000 | - | - | 50, 61, 47 [53 ± 7] |
- | - |
| 3500 | - | - | 37, 30, 36 [34 ± 4] |
- | - |
| 4000 | - | - | 41, 35, 34 [37 ± 4] |
- | - |
| 4500 | - | - | 35, 34, 36 [35 ± 1] |
- | - |
| 5000 | - | - | 35*, 33*, 38* [35 ± 3] |
- | - |
| Positive control | - | - | 900, 877, 860a) [879 ± 20] |
- | - |
*: Toxic effect was observed
-: Not tested
a): 2-AA; 2-Aminoanthracene, 10 μg/plate
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
positive with metabolic activation E. coli WP2 uvr A with metabolic activation was positive.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
